How to buy Neurotrope stock | $0.941

Neurotrope, Inc is a biotechnology business based in the US. Neurotrope shares (NTRP) are listed on the NASDAQ and all prices are listed in US Dollars. Neurotrope employs 5 staff and has a market cap (total outstanding shares value) of USD$22.4 million.

How to buy shares in Neurotrope

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Neurotrope. Find the stock by name or ticker symbol: NTRP. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neurotrope reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$0.941, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Neurotrope, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Neurotrope. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Neurotrope share price

Use our graph to track the performance of NTRP stocks over time.

Neurotrope shares at a glance

• Key figures

Information last updated 2020-12-02.

Latest market close	USD$0.941
52-week range	USD$0.6808 - USD$1.55
50-day moving average	USD$1.0323
200-day moving average	USD$1.1513
Wall St. target price	USD$1
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.477

Buy Neurotrope shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Neurotrope stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Neurotrope, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neurotrope price performance over time

Historical closes compared with the close of $0.941 from 2020-12-02

1 week (2021-01-13)	N/A
1 month (2020-12-20)	N/A
3 months (2020-10-20)	N/A
6 months (2020-07-20)	N/A

1 year (2020-01-20)	N/A
2 years (2019-01-20)	N/A
3 years (2018-01-20)	N/A
5 years (2016-01-20)	N/A

Neurotrope financials

Gross profit TTM	USD$0
Return on assets TTM	-27.73%
Return on equity TTM	-52.59%
Profit margin	0%
Book value	$1.171
Market capitalisation	USD$22.4 million

TTM: trailing 12 months

Shorting Neurotrope shares

There are currently 46,336 Neurotrope shares held short by investors – that's known as Neurotrope's "short interest". This figure is 75.5% down from 189,206 last month.

There are a few different ways that this level of interest in shorting Neurotrope shares can be evaluated.

Neurotrope's "short interest ratio" (SIR)

Neurotrope's "short interest ratio" (SIR) is the quantity of Neurotrope shares currently shorted divided by the average quantity of Neurotrope shares traded daily (recently around 243873.68421053). Neurotrope's SIR currently stands at 0.19. In other words for every 100,000 Neurotrope shares traded daily on the market, roughly 190 shares are currently held short.

However Neurotrope's short interest can also be evaluated against the total number of Neurotrope shares, or, against the total number of tradable Neurotrope shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neurotrope's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Neurotrope shares in existence, roughly 0 shares are currently held short) or 0.002% of the tradable shares (for every 100,000 tradable Neurotrope shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neurotrope.

Find out more about how you can short Neurotrope stock.

Neurotrope share dividends

We're not expecting Neurotrope to pay a dividend over the next 12 months.

Have Neurotrope's shares ever split?

Neurotrope's shares were split on a 1:32 basis on 12 January 2017. So if you had owned 32 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Neurotrope shares – just the quantity. However, indirectly, the new 3100% higher share price could have impacted the market appetite for Neurotrope shares which in turn could have impacted Neurotrope's share price.

Neurotrope share price volatility

Over the last 12 months, Neurotrope's shares have ranged in value from as little as $0.6808 up to $1.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurotrope's is 2.2587. This would suggest that Neurotrope's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Neurotrope overview

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

Frequently asked questions

• What percentage of Neurotrope is owned by insiders or institutions?

  Currently 12.251% of Neurotrope shares are held by insiders and 9.173% by institutions.

• How many people work for Neurotrope?

  Latest data suggests 5 work at Neurotrope.

• When does the fiscal year end for Neurotrope?

  Neurotrope's fiscal year ends in December.

• Where is Neurotrope based?

  Neurotrope's address is: 1185 Avenue of the Americas, New York, NY, United States, 10036

• What is Neurotrope's ISIN number?

  Neurotrope's international securities identification number is: US64129T2078

• What is Neurotrope's CUSIP number?

  Neurotrope's Committee on Uniform Securities Identification Procedures number is: 64129T207